Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026
Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026
Company Drug

Johnson & Johnson Submits Second NDA for Nipocalimab to Treat Generalized Myasthenia Gravis

Fineline Cube Sep 13, 2024

Johnson & Johnson (NYSE: JNJ), a leading healthcare company based in the U.S., has reported...

Company Drug

Keymed Biosciences’ IL-4Rα mAb Stapokibart Receives NMPA Approval for Atopic Dermatitis Treatment

Fineline Cube Sep 13, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has announced that the...

Company Policy / Regulatory

South Korea’s MFDS Aims to Slash Drug Approval Times with New Innovation Plan

Fineline Cube Sep 13, 2024

South Korea’s Ministry of Food and Drug Safety (MFDS) has unveiled an ambitious plan to...

Company Deals Digital

Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion

Fineline Cube Sep 13, 2024

Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...

Company Deals

Shanghai Bao Pharmaceutical and Subsidiary Secure Commercialization Rights Deal for SJ02 with Organon China

Fineline Cube Sep 13, 2024

Shanghai Bao Pharmaceutical, a Chinese pharmaceutical company, along with its wholly-owned subsidiary Suzhou Centergene Pharmaceuticals,...

Company Deals

ChemPartner Pharmatech Enters Strategic Partnership with Malaysian Entities to Develop Innovative Drugs

Fineline Cube Sep 13, 2024

ChemPartner Pharmatech Co., Ltd (SHE: 300149), a leading pharmaceutical company based in China, has joined...

Company Deals

Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies

Fineline Cube Sep 13, 2024

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic...

Company Deals

Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations

Fineline Cube Sep 13, 2024

MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round,...

General/Other

Leadership Shuffle at China’s National Health Commission: Liu Jinfeng Steps in as Deputy Director

Fineline Cube Sep 13, 2024

The Ministry of Human Resources and Social Security has announced key leadership changes within the...

Company Deals

Autobio Diagnostics Partners with MBL to Advance Microbial Mass Spectrometry Technology

Fineline Cube Sep 13, 2024

Autobio Diagnostics Co., Ltd (SHA: 603658), a prominent player in China’s in vitro diagnostic market,...

Company Medical Device

Yestar Healthcare’s 2024 Interim Report Reflects Impact of Volume-Based Procurement on Revenue

Fineline Cube Sep 13, 2024

Yestar Healthcare Holdings Co., Ltd., a leading distributor and service provider for in vitro diagnostic...

Company Drug

Sanofi’s Dupixent Shows Promise in Phase III Trials for Rare Skin Disease and Chronic Hives

Fineline Cube Sep 12, 2024

Sanofi (EPA: SAN; NASDAQ: SNY), a leading French pharmaceutical company, has announced positive results from...

Company Policy / Regulatory

FDA Uncovers Data Management Failures in Medical Device Labs, Assessing Regulatory Impact

Fineline Cube Sep 12, 2024

Medical device manufacturers relying on laboratory services for testing and validation data have come under...

Company Legal / IP R&D

Oxford Nanopore Sets Sights on BGI in UK Courts Over Nanopore Sequencing Technology

Fineline Cube Sep 12, 2024

Oxford Nanopore Technologies plc (LON: ONT), a UK-based leader in nanopore sequencing technology, has disclosed...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Partners with Haier Biomedical for Pharmaceutical Industry Digitalization

Fineline Cube Sep 12, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced a...

Company Deals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Fineline Cube Sep 12, 2024

Signet Therapeutics, a pioneering biopharmaceutical company in China specializing in cancer targeted therapies based on...

Policy / Regulatory

China Aims to Fortify Insurance Industry by 2035 with New State Council Directives

Fineline Cube Sep 12, 2024

The State Council has issued the “Several Opinions on Strengthening Supervision, Preventing Risks, and Promoting...

Company Drug

Suzhou GenAssist Launches First-of-Its-Kind Base Editing Drug Trial for Duchenne Muscular Dystrophy

Fineline Cube Sep 12, 2024

Suzhou GenAssist Therapeutic Co., Ltd, a biopharmaceutical company based in China, has announced the commencement...

Company Medical Device

Siemens Healthineers’ 7T MRI System Terra. X Receives NMPA Marketing Approval

Fineline Cube Sep 12, 2024

Siemens Healthineers AG has secured marketing approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting

Fineline Cube Sep 12, 2024

Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...

Posts pagination

1 … 330 331 332 … 698

Recent updates

  • Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II
  • TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal
  • Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications
  • Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody
  • Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.